FindTrial
Sign In

The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521163-12-01
Enrollment
10
Registered
2025-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' Orbitopathy

Brief summary

FAPI uptake in active GO versus inactive GO on PET-MRI

Detailed description

Relation MRI results (edema), clinical symptoms, and lab values to FAPI-uptake on PET.

Interventions

DRUG68GA-FAPI-46

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
FAPI uptake in active GO versus inactive GO on PET-MRI—

Secondary

MeasureTime frame
Relation MRI results (edema), clinical symptoms, and lab values to FAPI-uptake on PET.—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026